Concert Pharmaceuticals, Inc. (CNCE) Is At $19.60 Formed Wedge; Macatawa Bank (MCBC) Has 1.12 Sentiment

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Logo

Macatawa Bank Corp (MCBC) investors sentiment decreased to 1.12 in 2018 Q1. It’s down -0.03, from 1.15 in 2017Q4. The ratio fall, as 28 active investment managers increased and started new stock positions, while 25 cut down and sold their stakes in Macatawa Bank Corp. The active investment managers in our database reported: 9.46 million shares, up from 9.14 million shares in 2017Q4. Also, the number of active investment managers holding Macatawa Bank Corp in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 19 Increased: 19 New Position: 9.

Concert Pharmaceuticals, Inc. (CNCE) formed wedge down with $18.42 target or 6.00% below today’s $19.60 share price. Concert Pharmaceuticals, Inc. (CNCE) has $458.56M valuation. The stock increased 1.77% or $0.34 during the last trading session, reaching $19.6. About 146,086 shares traded. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 41.24% since June 13, 2017 and is uptrending. It has outperformed by 28.67% the S&P500. Some Historical CNCE News: ; 06/03/2018 Concert Pharmaceuticals Present at Upcoming Investor Conferences; 26/04/2018 – Concert Pharma Presenting at UBS Conference May 22; 23/04/2018 – Research Report Identifies Signature Bank, Concert Pharmaceuticals, Easterly Government Properties, Hilltop, Columbia Banking S; 02/04/2018 – Concert Pharma Closes Below 50-Day Moving Average: Technicals; 03/05/2018 – Concert Pharmaceuticals Cash, Cash Equivalents and Investments at March 31 Totaled $191M; 15/05/2018 – Ghost Tree Capital Buys New 1.5% Position in Concert Pharma; 14/05/2018 – Great Point Partners LLC Exits Position in Concert Pharma; 25/04/2018 – Concert Pharmaceuticals: Topline Phase 2a Data From the 4 Mg and 8 Mg Cohorts Expected in Fourth Qtr of 2018; 03/05/2018 – Concert Pharmaceuticals Expects Cash, Cash Equivalents and Investments as of March 31, 2018 to Be Sufficient to Fund the Co Into 2021; 25/04/2018 – CONCERT PHARMACEUTICALS INC – PHASE 2B CLINICAL TRIAL EVALUATING CTP-543 IS EXPECTED TO BEGIN IN 2019

Investors sentiment decreased to 1.37 in 2018 Q1. Its down 1.25, from 2.62 in 2017Q4. It dropped, as 13 investors sold Concert Pharmaceuticals, Inc. shares while 33 reduced holdings. 29 funds opened positions while 34 raised stakes. 16.64 million shares or 7.42% more from 15.49 million shares in 2017Q4 were reported. Cadence Lc holds 0.12% or 82,240 shares in its portfolio. D E Shaw & Inc has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Balyasny Asset Ltd holds 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) or 11,995 shares. The Massachusetts-based Massachusetts Serv Com Ma has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Sterling Cap Mgmt Lc has 0.01% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Ghost Tree Capital Llc reported 1.62% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Clarivest Asset Mngmt Lc has 108,652 shares for 0.04% of their portfolio. Renaissance Ltd Llc holds 494,200 shares or 0.01% of its portfolio. Morgan Stanley owns 89,858 shares. Arrowstreet Cap Limited Partnership, Massachusetts-based fund reported 291,950 shares. Bank Of New York Mellon reported 157,644 shares. Bowling Portfolio Mngmt Ltd Llc accumulated 17,405 shares. State Street invested in 0% or 381,912 shares. Bvf Inc Il reported 1.93M shares stake. Element Cap Mngmt Limited Liability Corp reported 0.01% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE).

Since January 16, 2018, it had 0 insider buys, and 6 sales for $2.60 million activity. Shares for $372,402 were sold by ALDRICH RICHARD. On Tuesday, April 17 Cassella James V sold $213,510 worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) or 10,582 shares.

Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Concert Pharmaceuticals had 25 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has “Buy” rating given on Friday, January 12 by Stifel Nicolaus. H.C. Wainwright maintained the shares of CNCE in report on Friday, November 10 with “Buy” rating. Mizuho downgraded it to “Neutral” rating and $23 target in Friday, January 12 report. UBS maintained Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Tuesday, December 19 with “Buy” rating. On Wednesday, September 9 the stock rating was initiated by Aegis Capital with “Buy”. On Monday, November 6 the stock rating was maintained by Mizuho with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $20.0 target in Monday, September 18 report. Stifel Nicolaus initiated the stock with “Buy” rating in Friday, July 1 report. Brean Capital initiated the stock with “Buy” rating in Wednesday, August 12 report. As per Wednesday, March 9, the company rating was maintained by JMP Securities.

Analysts await Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report earnings on August, 14. They expect $-0.62 earnings per share, down 6.90% or $0.04 from last year’s $-0.58 per share. After $-0.19 actual earnings per share reported by Concert Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 226.32% negative EPS growth.

Since January 1, 0001, it had 1 insider buy, and 0 sales for $22,859 activity.

The stock decreased 0.41% or $0.05 during the last trading session, reaching $12.09. About 31,817 shares traded. Macatawa Bank Corporation (MCBC) has risen 28.03% since June 13, 2017 and is uptrending. It has outperformed by 15.46% the S&P500. Some Historical MCBC News: ; 26/04/2018 – Macatawa Bank 1Q EPS 17c; 26/04/2018 – MACATAWA BANK CORP QTRLY SHR $0.17; 30/04/2018 – Macatawa Bank Corporation Declares Quarterly Dividend; 19/04/2018 DJ Macatawa Bank Corporation, Inst Holders, 1Q 2018 (MCBC)

Elizabeth Park Capital Advisors Ltd. holds 2.69% of its portfolio in Macatawa Bank Corporation for 917,176 shares. Banc Funds Co Llc owns 610,110 shares or 0.32% of their US portfolio. Moreover, Clenar Muke Llc has 0.11% invested in the company for 19,760 shares. The Michigan-based Aspen Investment Management Inc has invested 0.07% in the stock. Chicago Equity Partners Llc, a Illinois-based fund reported 52,905 shares.

Macatawa Bank Corporation operates as the bank holding firm for Macatawa Bank that provides commercial and personal banking services primarily in Western Michigan. The company has market cap of $411.27 million. The companyÂ’s deposit products include checking accounts, savings accounts and time deposits, transaction accounts, regular and money market savings accounts, and certificates of deposit. It has a 25.19 P/E ratio. The Company’s loan products portfolio comprises commercial and industrial loans offered to finance activities and equipment; commercial real estate loans primarily comprising construction and development loans, and multi-family and other non-residential real estate loans; retail loans that primarily consist of residential mortgage loans; and consumer loans, including automobile loans, home equity lines of credit and installment loans, home improvement loans, deposit account loans, and other loans for household and personal purposes.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Institutional Positions Chart